



Haleon plc: Completion of off-market purchase and Total Voting Rights and Capital

3 October 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that it has completed the off-market purchase of 60,526,315 ordinary shares of £0.01 each, repurchased from Pfizer Inc. ("Pfizer") for an aggregate purchase price of £230 million.

The off-market purchase includes (i) 30,161,278 ordinary shares which Haleon has cancelled and (ii) 30,365,037 ordinary shares which will be held as treasury shares.

As at 3 October 2024, the total number of ordinary shares issued by Haleon is 9,083,725,919, of which 30,365,037 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 9,053,360,882 and this figure may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Amanda Mellor
Company Secretary

Enquiries

Investors

Sonya Ghobrial +44 7392 784784
Rakesh Patel +44 7552 484646
Emma White +44 7823 523562

Email: investor-relations@haleon.com

Media

Zoë Bird +44 7736 746167
Gemma Thomas +44 7985 175048

Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information please visit www.haleon.com

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCMJBBTMTMMBBI